178 related articles for article (PubMed ID: 22820754)
41. PRO12ALA POLYMORPHISM ASSOCIATION OF PPAR-γ GENE WITH BIOCHEMICAL PARAMETERS OF THE BLOOD IN PATIENTS WITH CHRONIC DIFFUSE LIVER DISEASES.
Prysyazhnyuk V
Georgian Med News; 2015 Sep; (246):35-40. PubMed ID: 26355313
[TBL] [Abstract][Full Text] [Related]
42. Association of PNPLA3 rs738409 G/C gene polymorphism with nonalcoholic fatty liver disease in children: a meta-analysis.
Tang S; Zhang J; Mei TT; Guo HQ; Wei XH; Zhang WY; Liu YL; Liang S; Fan ZP; Ma LX; Lin W; Liu YR; Qiu LX; Yu HB
BMC Med Genet; 2020 Aug; 21(1):163. PubMed ID: 32811452
[TBL] [Abstract][Full Text] [Related]
43. A Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio.
Chen S; Li Y; Li S; Yu C
J Gastroenterol Hepatol; 2008 Sep; 23(9):1415-8. PubMed ID: 18853997
[TBL] [Abstract][Full Text] [Related]
44. Variants of the human PPARG locus and the susceptibility to chronic periodontitis.
Folwaczny M; Manolis V; Markus C; Glas J
Innate Immun; 2011 Dec; 17(6):541-7. PubMed ID: 21252350
[TBL] [Abstract][Full Text] [Related]
45. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver.
Valenti L; Nobili V; Al-Serri A; Rametta R; Leathart JB; Zappa MA; Dongiovanni P; Fracanzani AL; Alterio A; Roviaro G; Daly AK; Fargion S; Day CP
J Hepatol; 2011 Dec; 55(6):1409-14. PubMed ID: 21777557
[TBL] [Abstract][Full Text] [Related]
46. Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease.
Yoneda M; Hotta K; Nozaki Y; Endo H; Uchiyama T; Mawatari H; Iida H; Kato S; Fujita K; Takahashi H; Kirikoshi H; Kobayashi N; Inamori M; Abe Y; Kubota K; Saito S; Maeyama S; Wada K; Nakajima A
Liver Int; 2009 Aug; 29(7):1078-85. PubMed ID: 19302184
[TBL] [Abstract][Full Text] [Related]
47. Influence of the Pro12Ala polymorphism of PPAR-gamma on age at onset and sRAGE levels in Alzheimer's disease.
Yao L; Li K; Zhang L; Yao S; Piao Z; Song L
Brain Res; 2009 Sep; 1291():133-9. PubMed ID: 19631630
[TBL] [Abstract][Full Text] [Related]
48. The association of nonalcoholic fatty liver disease with genetic polymorphisms: a multicenter study.
Uygun A; Ozturk K; Demirci H; Oztuna A; Eren F; Kozan S; Yilmaz Y; Kurt O; Turker T; Vatansever S; Alper E; Unsal B
Eur J Gastroenterol Hepatol; 2017 Apr; 29(4):441-447. PubMed ID: 28253210
[TBL] [Abstract][Full Text] [Related]
49. Genetic Variants in nicotinamide-N-methyltransferase (NNMT) gene are related to the stage of non-alcoholic fatty liver disease diagnosed by controlled attenuation parameter (CAP)-fibroscan.
Hasan EM; Abd Al Aziz RA; Sabry D; Darweesh SK; Badary HA; Elsharkawy A; Abouelkhair MM; Yosry A
J Gastrointestin Liver Dis; 2018 Sep; 27(3):265-272. PubMed ID: 30240470
[TBL] [Abstract][Full Text] [Related]
50. Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents.
Zusi C; Mantovani A; Olivieri F; Morandi A; Corradi M; Miraglia Del Giudice E; Dauriz M; Valenti L; Byrne CD; Targher G; Maffeis C
Dig Liver Dis; 2019 Nov; 51(11):1586-1592. PubMed ID: 31255630
[TBL] [Abstract][Full Text] [Related]
51. [Association of both peroxisome proliferator-activated receptor, gene-gene interactions and the body mass index].
Luo WS; Guo ZR; Wu M; Chen Q; Zhou ZY; Yu H; Zhang LJ; Liu JC
Zhonghua Liu Xing Bing Xue Za Zhi; 2012 Jul; 33(7):740-5. PubMed ID: 22968028
[TBL] [Abstract][Full Text] [Related]
52. Association between PPARGC1A single nucleotide polymorphisms and increased risk of nonalcoholic fatty liver disease among Iranian patients with type 2 diabetes mellitus.
Saremi L; Lotfıpanah S; Mohammadi M; Hosseinzadeh H; Hosseini-Khah Z; Johari B; Saltanatpour Z
Turk J Med Sci; 2019 Aug; 49(4):1089-1094. PubMed ID: 31390852
[TBL] [Abstract][Full Text] [Related]
53. Sex and Menopause Modify the Effect of Single Nucleotide Polymorphism Genotypes on Fibrosis in NAFLD.
Wegermann K; Garrett ME; Zheng J; Coviello A; Moylan CA; Abdelmalek MF; Chow SC; Guy CD; Diehl AM; Ashley-Koch A; Suzuki A
Hepatol Commun; 2021 Apr; 5(4):598-607. PubMed ID: 33860118
[TBL] [Abstract][Full Text] [Related]
54. PPARGC1A rs3736265 G>A polymorphism is associated with decreased risk of type 2 diabetes mellitus and fasting plasma glucose level.
Zhu L; Huang Q; Xie Z; Kang M; Ding H; Chen B; Chen Y; Liu C; Wang Y; Tang W
Oncotarget; 2017 Jun; 8(23):37308-37320. PubMed ID: 28418876
[TBL] [Abstract][Full Text] [Related]
55. The role of SAMM50 in non-alcoholic fatty liver disease: from genetics to mechanisms.
Li Z; Shen W; Wu G; Qin C; Zhang Y; Wang Y; Song G; Xiao C; Zhang X; Deng G; Wang R; Wang X
FEBS Open Bio; 2021 Jul; 11(7):1893-1906. PubMed ID: 33728819
[TBL] [Abstract][Full Text] [Related]
56. Peroxisome proliferators-activated receptor γ2 Pro12Ala variant is associated with body mass index in non-alcoholic fatty liver disease patients.
Gupta AC; Chaudhory AK; Sukriti ; Pande C; Sakhuja P; Singh Y; Basir SF; Sarin SK
Hepatol Int; 2010 Dec; 5(1):575-80. PubMed ID: 21442055
[TBL] [Abstract][Full Text] [Related]
57. Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD).
Yoneda M; Hotta K; Nozaki Y; Endo H; Uchiyama T; Mawatari H; Iida H; Kato S; Hosono K; Fujita K; Yoneda K; Takahashi H; Kirikoshi H; Kobayashi N; Inamori M; Abe Y; Kubota K; Saito S; Maeyama S; Wada K; Nakajima A
BMC Gastroenterol; 2008 Jun; 8():27. PubMed ID: 18588668
[TBL] [Abstract][Full Text] [Related]
58. rs7903146 (C/T) polymorphism of Transcription factor 7 like 2 (TCF7L-2) gene is independently associated with non-alcoholic fatty liver disease in Asian Indians.
Bhatt SP; Misra A; Pandey RM
Diabetes Metab Syndr; 2020; 14(3):175-180. PubMed ID: 32142998
[TBL] [Abstract][Full Text] [Related]
59. Solute carrier family 2 member 1 is involved in the development of nonalcoholic fatty liver disease.
Vazquez-Chantada M; Gonzalez-Lahera A; Martinez-Arranz I; Garcia-Monzon C; Regueiro MM; Garcia-Rodriguez JL; Schlangen KA; Mendibil I; Rodriguez-Ezpeleta N; Lozano JJ; Banasik K; Justesen JM; Joergensen T; Witte DR; Lauritzen T; Hansen T; Pedersen O; Veyrie N; Clement K; Tordjman J; Tran A; Le Marchand-Brustel Y; Buque X; Aspichueta P; Echevarria-Uraga JJ; Martin-Duce A; Caballeria J; Gual P; Castro A; Mato JM; Martinez-Chantar ML; Aransay AM
Hepatology; 2013 Feb; 57(2):505-14. PubMed ID: 22961556
[TBL] [Abstract][Full Text] [Related]
60. ASSOCIATION ANALYSIS OF PIOGLITAZONE EFFECTIVENESS IN TREATMENT OF NAFLD PATIENTS WITH OBESITY AND PPARG RS1801282 (PRO12ALA) GENOTYPE.
Shypulin VP; Martynchuk OA; Rudenko NN; Koliada AK; Tishchenko VV; Melnyk NH
Wiad Lek; 2021; 74(7):1617-1621. PubMed ID: 34459761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
